繁體中文
返回
- English
- 繁體中文
- 简体中文
- 深色
- 淺色
立即開戶
bluebird bio | 8-K: bluebird bio Reports Fourth Quarter and 2023 Annual Results and Highlights Operational Progress and 2024 Guidance
bluebird bio | 8-K: Current report
bluebird bio | 8-K:重大事件
牛牛AI助理已提取核心訊息
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will...Show More
On March 26, 2024, bluebird bio, Inc. disclosed its financial results for the fourth quarter and the full year ended December 31, 2023, and provided updates on its operational progress and guidance for 2024. The company reported a full year 2023 revenue of $29.5 million, with $7.8 million generated in the fourth quarter. bluebird bio also announced a $175 million term loan facility with Hercules Capital, which is expected to extend the company's cash runway through Q1 2026. The company has seen 9 patient starts in 2024 for its gene therapies ZYNTEGLO and SKYSONA, and anticipates 85 to 105 patient starts across its portfolio in 2024. A government outcomes-based agreement for sickle cell disease was signed with Michigan Medicaid, and 62 qualified treatment centers have been activated. However, bluebird bio also announced that it will restate its consolidated financial statements for 2022 and for the first three quarters of both 2022 and 2023 due to accounting errors related to lease agreements with contract manufacturers. The restatement is expected to result in an increase in lease assets and lease liabilities, as well as an increase in non-cash interest expense, but will not impact the company's cash position or revenue. The company plans to file its restated 2023 Form 10-K by April 16, 2024.
2024年3月26日,藍鳥生物公司披露了截至2023年12月31日的第四季度和全年財務業績,並提供了其2024年的最新運營進展和指導。該公司報告稱,2023年全年收入爲2950萬美元,第四季度收入爲780萬美元。藍鳥生物還宣佈向Hercules Capital提供1.75億美元的定期貸款,預計該公司的現金流將延長至2026年第一季度。該公司的基因療法ZYNTEGLO和SKYSONA在2024年有9名患者開始接受治療,預計到2024年,其產品組合中將有85至105名患者開始接受治療。與密歇根州醫療補助計劃簽署了一項以政府結果爲基礎的鐮狀細胞病協議,並啓動了62個合格的治療中心。但是,藍鳥生物還宣...展開全部
2024年3月26日,藍鳥生物公司披露了截至2023年12月31日的第四季度和全年財務業績,並提供了其2024年的最新運營進展和指導。該公司報告稱,2023年全年收入爲2950萬美元,第四季度收入爲780萬美元。藍鳥生物還宣佈向Hercules Capital提供1.75億美元的定期貸款,預計該公司的現金流將延長至2026年第一季度。該公司的基因療法ZYNTEGLO和SKYSONA在2024年有9名患者開始接受治療,預計到2024年,其產品組合中將有85至105名患者開始接受治療。與密歇根州醫療補助計劃簽署了一項以政府結果爲基礎的鐮狀細胞病協議,並啓動了62個合格的治療中心。但是,藍鳥生物還宣佈,由於與合同製造商的租賃協議有關的會計錯誤,它將重報其2022年以及2022年和2023年前三個季度的合併財務報表。重報預計將導致租賃資產和租賃負債增加,以及非現金利息支出的增加,但不會影響公司的現金狀況或收入。該公司計劃在2024年4月16日之前提交其重報的2023年10-K表格。
有用
沒用
譯文內容由第三人軟體翻譯。
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
資訊熱榜
更新時間